Comparison of the NOW Influenza A & B, NOW Flu A, NOW Flu B, and Directigen Flu A+B assays, and immunofluorescence with viral culture for the detection of influenza A and B viruses.

To evaluate the Binax NOW Influenza A & B combination assay, we tested upper respiratory tract samples in parallel with the Binax NOW Flu A and Binax NOW Flu B assays, the Becton-Dickinson Directigen Flu A+B assay, and immunofluorescence, and the results were compared with viral culture. Of the 521 samples tested, influenza A was cultured from 113 and influenza B from 6. There were no significant differences in the performance of all rapid antigen tests, with sensitivities of 53% to 59% for detecting influenza A compared with culture and immunofluorescence (80%). The sensitivities for all rapid tests were significantly higher for nasopharyngeal samples than for throat swabs. The Binax NOW Influenza A & B assay performed as well as other rapid assays. Commercial antigen detection assays are useful tools for the rapid diagnosis of influenza; however, confirmatory testing is always recommended. The use of nasopharyngeal samples for all rapid detection methods should be strongly encouraged.